Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New UK Market Surveillance Levy Could Cost Medtech Companies Millions Each Year

This article was originally published in The Gray Sheet

Executive Summary

The exact size of the fee is not yet known, but the UK's Medicines and Healthcare products Regulatory Agency apparently says it will be necessary to maintain fully functioning market oversight.

You may also be interested in...



NICE Cost-Recovery-Plan Pause Is Welcome News For UK Industry

The UK National Institute for Health and Care Excellence will wait for the government to finalize its life sciences strategy before deciding on whether to go ahead with its plan to levy a fee for technology appraisals. Pharmaceutical and medtech companies say the delay by NICE will allow more time for their concerns over the proposal to be explored.

NICE Cost Recovery Plans Pause Is Welcome News For UK Industry

UK health technology body NICE will wait for the government to finalize its life sciences strategy before deciding on whether to go ahead with its plan to levy a fee for technology appraisals. Pharmaceutical and medtech companies say the delay will allow more time for their concerns over the proposal to be explored.

Europe Readies For Big Changes In Device Postmarket Surveillance

Europe may be on the cusp of a big drive toward a more clearly organized and more transparent postmarket vigilance system with new funds directed at the issue in the wake of device safety scandals. The European Commission recently launched the second phase of its joint action plan of near-term device and diagnostics reforms, pushing postmarket surveillance to the top of its agenda.

Topics

UsernamePublicRestriction

Register

MT034741

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel